Sana Biotechnology Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.42
- Today's High:
- $5.78
- Open Price:
- $5.55
- 52W Low:
- $2.99
- 52W High:
- $8.005
- Prev. Close:
- $5.57
- Volume:
- 579289
Company Statistics
- Market Cap.:
- $1.15 billion
- Book Value:
- 1.803
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.51%
- Return on Equity TTM:
- -72.73%
Company Profile
Sana Biotechnology Inc had its IPO on 2021-02-04 under the ticker symbol SANA.
The company operates in the Healthcare sector and Biotechnology industry. Sana Biotechnology Inc has a staff strength of 424 employees.
Stock update
Shares of Sana Biotechnology Inc opened at $5.55 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.42 - $5.78, and closed at $5.69.
This is a +2.15% increase from the previous day's closing price.
A total volume of 579,289 shares were traded at the close of the day’s session.
In the last one week, shares of Sana Biotechnology Inc have increased by +6.55%.
Sana Biotechnology Inc's Key Ratios
Sana Biotechnology Inc has a market cap of $1.15 billion, indicating a price to book ratio of 1.3917 and a price to sales ratio of 0.
In the last 12-months Sana Biotechnology Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-338961984. The EBITDA ratio measures Sana Biotechnology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sana Biotechnology Inc’s operating margin was 0% while its return on assets stood at -26.51% with a return of equity of -72.73%.
In Q2, Sana Biotechnology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Sana Biotechnology Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sana Biotechnology Inc’s profitability.
Sana Biotechnology Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.4401. Its price to sales ratio in the trailing 12-months stood at 0.
Sana Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $707.15 million
- Total Liabilities
- $112.11 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.58 million
- Dividend Payout Ratio
- 0%
Sana Biotechnology Inc ended 2024 with $707.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $707.15 million while shareholder equity stood at $355.03 million.
Sana Biotechnology Inc ended 2024 with $0 in deferred long-term liabilities, $112.11 million in other current liabilities, 20000.00 in common stock, $-1250958000.00 in retained earnings and $140.63 million in goodwill. Its cash balance stood at $173.79 million and cash and short-term investments were $325.92 million. The company’s total short-term debt was $12,890,000 while long-term debt stood at $0.
Sana Biotechnology Inc’s total current assets stands at $338.62 million while long-term investments were $0.00 and short-term investments were $152.13 million. Its net receivables were $0 compared to accounts payable of $3.09 million and inventory worth $0.
In 2024, Sana Biotechnology Inc's operating cash flow was $0 while its capital expenditure stood at $1.58 million.
Comparatively, Sana Biotechnology Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.69
- 52-Week High
- $8.005
- 52-Week Low
- $2.99
- Analyst Target Price
- $10
Sana Biotechnology Inc stock is currently trading at $5.69 per share. It touched a 52-week high of $8.005 and a 52-week low of $8.005. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $5.69 and 200-day moving average was $4.98 The short ratio stood at 25.14 indicating a short percent outstanding of 0%.
Around 1042.9% of the company’s stock are held by insiders while 9278.7% are held by institutions.
Frequently Asked Questions About Sana Biotechnology Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington’s disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.